Alcon (ACL) Begins Phase 2 Trial of NovaBay's (NBY) NVC-422
More News related to ACL
- Alcon Posts 5.9 Percent Sales Growth for Third Quarter
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Alcon (ACL) and Potentia Pharma Sign Licensing and Purchasing Agreement for Macular Degeneration Treatment
- Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
- Alcon Announces Third Quarter 2009 Financial Release and Conference Call Dates
More News related to NBY
- NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
- NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting
- NovaBay Pharmaceuticals to Present at 8th Annual Bio Investor Forum 2009 in San Francisco
- NovaBay Pharmaceuticals (NBY) Names Dr. Mark Andersone as Chief Scientific Officer
- NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Late yesterday, Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc. (AMEX: NBY), announced today that Alcon has begun treating patients in a Phase 2 clinical trial of NovaBay's patented lead Aganocide(R) compound, NVC-422, for viral conjunctivitis, a type of "pink eye." Conjunctivitis is a pervasive and painful condition that affects both adults and children, leading to more than four million doctor and emergency room visits in the United States each year.
NovaBay has a licensing and research collaboration agreement with Alcon, the world's leading eye care company, for use of its Aganocide(R) compounds in the eye, ear and sinus, and in contact lens solutions.
The Phase 2 multi-center, randomized, placebo-controlled trial is designed to determine the safety and efficacy of NVC-422 in people with viral conjunctivitis. The study calls for enrolling approximately 250 patients at more than 30 medical centers, mostly in the United States.
Related Categories
Corporate NewsStocks Mentioned
-0.09
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
